Business Description
Autolus Therapeutics PLC
NAICS : 325412
SIC : 2834
191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Compare
Compare
Traded in other countries / regions
6A3A.Germany
•
AUTL.USA
Description
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.58 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.7 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -7 | |||||
| 3-Year EPS without NRI Growth Rate | -11.5 | |||||
| 3-Year FCF Growth Rate | -10.6 | |||||
| 3-Year Book Growth Rate | -18.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.64 | |||||
| 9-Day RSI | 64.73 | |||||
| 14-Day RSI | 63.36 | |||||
| 6-1 Month Momentum % | -32.18 | |||||
| 12-1 Month Momentum % | -48.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.29 | |||||
| Quick Ratio | 7.29 | |||||
| Cash Ratio | 6.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -21344.59 | |||||
| Net Margin % | -18806.56 | |||||
| ROE % | -58.3 | |||||
| ROA % | -45.24 | |||||
| ROIC % | -174.36 | |||||
| ROC (Joel Greenblatt) % | -342.65 | |||||
| ROCE % | -56.77 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 328.84 | |||||
| PB Ratio | 1.37 | |||||
| Price-to-Tangible-Book | 1.42 | |||||
| EV-to-EBIT | -0.57 | |||||
| EV-to-EBITDA | -0.62 | |||||
| EV-to-Revenue | 123.82 | |||||
| EV-to-Forward-Revenue | 765.86 | |||||
| EV-to-FCF | -1.06 | |||||
| Price-to-Net-Current-Asset-Value | 1.91 | |||||
| Price-to-Net-Cash | 2.59 | |||||
| Earnings Yield (Greenblatt) % | -174.47 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:AUTL
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.823 | ||
| EPS (TTM) ($) | -1.85 | ||
| Beta | 1.73 | ||
| Volatility % | 57.25 | ||
| 14-Day RSI | 63.36 | ||
| 14-Day ATR ($) | 0.279714 | ||
| 20-Day SMA ($) | 3.1915 | ||
| 12-1 Month Momentum % | -48.78 | ||
| 52-Week Range ($) | 1.96 - 7.9 | ||
| Shares Outstanding (Mil) | 90.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Autolus Therapeutics PLC Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||